

Gemtesa® (vibegron) – New indication

- On December 18, 2024, the FDA approved Sumitomo Pharma's <u>Gemtesa (vibegron)</u>, for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency in adult males on pharmacological therapy for benign prostatic hyperplasia (BPH).
- Gemtesa is also approved for the treatment of OAB with symptoms of urge urinary incontinence, urgency, and urinary frequency in adults.
- The approval of Gemtesa for the new indication was based on a randomized, double-blind, placebo-controlled study in 1,105 male patients at least 45 years of age with OAB on pharmacological therapy (ie, treatment with an alpha blocker, with or without a 5-alpha reductase inhibitor) for BPH. Patients were randomized to Gemtesa or placebo for 24 weeks. The co-primary endpoints were change from baseline in the average daily number of micturitions and the average daily number of "need to urinate immediately" (urgency) episodes at week 12.
 - The change in average daily number of micturitions was -2.04 with Gemtesa vs. -1.30 with placebo (difference -0.74, 95% CI: -1.02, -0.46).
 - The change in average daily number of urgency episodes was -2.88 with Gemtesa vs. -1.93 with placebo (difference -0.95, 95% CI: -1.37, -0.54).
- The recommended dosage of Gemtesa is one 75 mg tablet orally, once daily with or without food.



At Optum, we help create a healthier world, one insight, one connection, one person at a time. All Optum trademarks and logos are owned by Optum, Inc., in the U.S. and other jurisdictions. All other trademarks are the property of their respective owners. This document contains information that is considered proprietary to Optum Rx and should not be reproduced without the express written consent of Optum Rx. RxNews[®] is published by the Optum Rx Clinical Services Department.